Aspen Aerogels (NYSE:ASPN) Price Target Lowered to $6.00 at TD Cowen

Aspen Aerogels (NYSE:ASPN) had its price target cut by TD Cowen from $7.00 to $6.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The brokerage currently has a “buy” rating on the construction company’s stock. TD Cowen’s target price points to a potential upside of 99.67% from the stock’s previous close.

Several other equities analysts have also recently issued reports on ASPN. Barclays decreased their target price on shares of Aspen Aerogels from $6.00 to $4.00 and set an “underweight” rating for the company in a research note on Friday, November 7th. Canaccord Genuity Group lowered their target price on shares of Aspen Aerogels from $10.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Aspen Aerogels in a research note on Monday, December 29th. Finally, Zacks Research upgraded Aspen Aerogels from a “strong sell” rating to a “hold” rating in a research report on Thursday, January 15th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $4.50.

Aspen Aerogels Stock Performance

Shares of Aspen Aerogels stock traded up $0.44 on Thursday, reaching $3.01. 1,292,704 shares of the stock were exchanged, compared to its average volume of 1,573,191. The business has a 50 day moving average price of $3.31 and a two-hundred day moving average price of $5.08. The firm has a market capitalization of $248.36 million, a price-to-earnings ratio of -0.81 and a beta of 2.99. Aspen Aerogels has a twelve month low of $2.30 and a twelve month high of $9.78. The company has a quick ratio of 3.33, a current ratio of 3.94 and a debt-to-equity ratio of 0.28.

Aspen Aerogels (NYSE:ASPN) last announced its quarterly earnings data on Wednesday, February 25th. The construction company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.07). The business had revenue of $41.34 million for the quarter, compared to analyst estimates of $44.25 million. Aspen Aerogels had a negative net margin of 86.52% and a negative return on equity of 0.20%. The business’s revenue was down 66.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.14 earnings per share. Aspen Aerogels has set its Q1 2026 guidance at -0.280–0.240 EPS. Analysts anticipate that Aspen Aerogels will post 0.17 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of ASPN. Invesco Ltd. raised its stake in shares of Aspen Aerogels by 237.9% in the 4th quarter. Invesco Ltd. now owns 4,129,934 shares of the construction company’s stock valued at $11,688,000 after acquiring an additional 2,907,558 shares during the period. Federated Hermes Inc. acquired a new stake in Aspen Aerogels in the 2nd quarter valued at approximately $10,459,000. Needham Investment Management LLC raised its position in Aspen Aerogels by 26.5% in the fourth quarter. Needham Investment Management LLC now owns 4,351,700 shares of the construction company’s stock valued at $12,315,000 after purchasing an additional 912,000 shares during the period. JPMorgan Chase & Co. raised its position in Aspen Aerogels by 105.4% in the second quarter. JPMorgan Chase & Co. now owns 1,246,506 shares of the construction company’s stock valued at $7,379,000 after purchasing an additional 639,753 shares during the period. Finally, Goldman Sachs Group Inc. lifted its stake in Aspen Aerogels by 89.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,274,356 shares of the construction company’s stock worth $8,143,000 after purchasing an additional 602,586 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Key Aspen Aerogels News

Here are the key news stories impacting Aspen Aerogels this week:

• Positive Sentiment: Firm balance sheet and near-term cash boost — Aspen closed 2025 with $158.6M cash and expects a ~$37.6M GM commercial settlement in Q1 2026, which supports near-term liquidity and funds the strategic review. GlobeNewswire: Q4 & Full Year 2025 Results
• Positive Sentiment: Strategic review initiated — management engaged Piper Sandler to evaluate options (capital-structure optimization, asset sales, other actions) that could create shareholder value. The review gives the company flexibility to pursue transactions that might unlock value. GlobeNewswire: Strategic Review Announcement
• Positive Sentiment: Commercial momentum — Aspen highlighted a North Sea subsea pipeline award and expansion of European OEM relationships (e.g., Volvo), indicating continued project wins outside North America. GlobeNewswire: Commercial Developments
• Neutral Sentiment: Full earnings call/transcript coverage is available (management commentary expands on causes of the revenue decline, cost actions and outlook). Read the call transcript for Q&A details that could affect near‑term guidance interpretation. Seeking Alpha: Q4 2025 Earnings Call Transcript
• Negative Sentiment: Sharp revenue and GAAP profit deterioration — Q4 revenue fell to $41.3M (‑66% Y/Y) and the company reported a GAAP net loss of $72.9M (EPS ‑$0.88). Full‑year revenue dropped to $271.1M and included a $291.2M impairment tied to the Statesboro plant. These headline misses weigh on near‑term fundamentals. GlobeNewswire: Q4 & Full Year 2025 Results
• Negative Sentiment: Below‑consensus Q1 2026 guidance — Aspen issued Q1 revenue guidance of $35–$40M and EPS guidance of ‑$0.28 to ‑$0.24 (below consensus), signaling continued softness in thermal‑barrier (EV) volumes and an expected net loss in Q1. GlobeNewswire: Q1 2026 Outlook
• Negative Sentiment: Potential litigation risk — plaintiff firm Johnson Fistel announced an investigation into potential claims involving Aspen’s executives, which could lead to legal costs or distraction. GlobeNewswire: Johnson Fistel Investigation Notice

Aspen Aerogels Company Profile

Aspen Aerogels, Inc, headquartered in Northborough, Massachusetts, develops and manufactures high-performance aerogel insulation materials and custom engineered solutions. Founded in 2001 as a spin-out from Department of Energy research, the company pursued an initial public offering on the NYSE in 2014 under the ticker ASPN. Aspen Aerogels combines proprietary aerogel formulations with advanced manufacturing processes to deliver products known for their low thermal conductivity, lightweight construction and robust mechanical properties.

The company’s product portfolio spans blanket insulation, boards, and custom shapes built around several proprietary brands, including Pyrogel, Cryogel and Spaceloft.